| pubmed-article:16207471 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16207471 | lifeskim:mentions | umls-concept:C0021756 | lld:lifeskim |
| pubmed-article:16207471 | lifeskim:mentions | umls-concept:C1167250 | lld:lifeskim |
| pubmed-article:16207471 | lifeskim:mentions | umls-concept:C1173313 | lld:lifeskim |
| pubmed-article:16207471 | lifeskim:mentions | umls-concept:C0037083 | lld:lifeskim |
| pubmed-article:16207471 | lifeskim:mentions | umls-concept:C0001721 | lld:lifeskim |
| pubmed-article:16207471 | lifeskim:mentions | umls-concept:C0286651 | lld:lifeskim |
| pubmed-article:16207471 | lifeskim:mentions | umls-concept:C1710082 | lld:lifeskim |
| pubmed-article:16207471 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:16207471 | pubmed:dateCreated | 2005-10-6 | lld:pubmed |
| pubmed-article:16207471 | pubmed:abstractText | Although the immunomodulatory properties of statins are in part independent of their lipid-lowering effects, cholesterol is a major component of lipid rafts. We therefore studied the effects of atorvastatin (AS) on the raft enrichment of the interleukin-2 receptor (IL-2R) beta chain previously described by us and on early IL-2R signaling events in activated human T cells. We found that concomitant AS exposure during a 3-day stimulation with phytohemagglutinin (PHA) attenuates activation-associated events, such as the enhanced surface expression of the raft marker GM-1 and the induced expression of the activation marker CD25 (the IL-2R alpha chain). In contrast, brief AS treatment after PHA stimulation increased GM-1 surface expression and virtually abolished the selective raft enrichment of the IL-2R beta chain. Although this AS-associated increase in GM-1 expression resembled that seen in the presence of the raft-disrupting cholesterol chelator methyl-beta-cyclodextrin (MBCD), the two agents had contrasting effects on the tyrosine phosphorylation of the IL-2R beta chain by exogenous IL-2: MBCD essentially abolished this event, whereas AS tended to enhance it and shifted its occurrence out of rafts. We conclude that AS affects IL-2R signaling by altering the raft enrichment of the IL-2R beta chain and propose that this effect is one mechanism underlying the immunomodulatory properties of statins. | lld:pubmed |
| pubmed-article:16207471 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16207471 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16207471 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16207471 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16207471 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16207471 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16207471 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16207471 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16207471 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16207471 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16207471 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16207471 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16207471 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16207471 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16207471 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:16207471 | pubmed:issn | 1081-5589 | lld:pubmed |
| pubmed-article:16207471 | pubmed:author | pubmed-author:Wills-KarpMar... | lld:pubmed |
| pubmed-article:16207471 | pubmed:author | pubmed-author:GoebelJensJ | lld:pubmed |
| pubmed-article:16207471 | pubmed:author | pubmed-author:ForrestKathyK | lld:pubmed |
| pubmed-article:16207471 | pubmed:author | pubmed-author:RoszmanThomas... | lld:pubmed |
| pubmed-article:16207471 | pubmed:author | pubmed-author:LoganBarbaraB | lld:pubmed |
| pubmed-article:16207471 | pubmed:author | pubmed-author:MieczkowskiAl... | lld:pubmed |
| pubmed-article:16207471 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16207471 | pubmed:volume | 53 | lld:pubmed |
| pubmed-article:16207471 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16207471 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16207471 | pubmed:pagination | 322-8 | lld:pubmed |
| pubmed-article:16207471 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:16207471 | pubmed:meshHeading | pubmed-meshheading:16207471... | lld:pubmed |
| pubmed-article:16207471 | pubmed:meshHeading | pubmed-meshheading:16207471... | lld:pubmed |
| pubmed-article:16207471 | pubmed:meshHeading | pubmed-meshheading:16207471... | lld:pubmed |
| pubmed-article:16207471 | pubmed:meshHeading | pubmed-meshheading:16207471... | lld:pubmed |
| pubmed-article:16207471 | pubmed:meshHeading | pubmed-meshheading:16207471... | lld:pubmed |
| pubmed-article:16207471 | pubmed:meshHeading | pubmed-meshheading:16207471... | lld:pubmed |
| pubmed-article:16207471 | pubmed:meshHeading | pubmed-meshheading:16207471... | lld:pubmed |
| pubmed-article:16207471 | pubmed:meshHeading | pubmed-meshheading:16207471... | lld:pubmed |
| pubmed-article:16207471 | pubmed:meshHeading | pubmed-meshheading:16207471... | lld:pubmed |
| pubmed-article:16207471 | pubmed:meshHeading | pubmed-meshheading:16207471... | lld:pubmed |
| pubmed-article:16207471 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:16207471 | pubmed:articleTitle | Atorvastatin affects interleukin-2 signaling by altering the lipid raft enrichment of the interleukin-2 receptor beta chain. | lld:pubmed |
| pubmed-article:16207471 | pubmed:affiliation | Division of Nephrology and Hypertension, Cincinnati Children's Hospital, Cincinnati, OH 45229, USA. Jens.Goebel@cchmc.org | lld:pubmed |
| pubmed-article:16207471 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16207471 | pubmed:publicationType | In Vitro | lld:pubmed |
| pubmed-article:16207471 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:16207471 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:16207471 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
